Brief: Grand Pharmaceutical Says Co, XELTIS AG Entered Strategic Cooperation Agreement
18/07/2022 11:27
July 18 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* GROUP AND XELTIS AG ENTERED INTO A STRATEGIC COOPERATION
AGREEMENT
* GROUP WILL USE EUR 15 MILLION TO ACQUIRE 11% EQUITY
INTERESTS IN
XELTIS, AMONG OTHERS
* HAS PRE-EMPTIVE NEGOTIATION RIGHT FOR PRODUCTS OF XELTIS
DEVELOPED IN OTHER INDICATION AREAS, IN GREATER CHINA REGION
* UNDER DEAL, TO ALSO OBTAIN EXCLUSIVE DEVELOPMENT,
PRODUCTION AND
COMMERCIALIZATION RIGHTS OF AXESS
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement